Navigation Links
Cloretazine in Medical News

Vion Pharmaceuticals Receives a Standard Review from the FDA for Its New Drug Application for Onrigin(TM)

...ected, including Vion's potential inability to obtain regulatory approval for its products, particularly Onrigin(TM) (laromustine) Injection (formerly cloretazine (VNP40101M)), delays in the regulatory approval process, particularly for Onrigin(TM) (laromustine) Injection, including possible delays in the FD...

Vion Pharmaceuticals' New Drug Application for Onrigin(TM)Accepted For Review by the FDA

...xpected, including Vion's potential inability to obtain regulatory approval for its products, particularly Onrigin (laromustine) Injection (formerly cloretazine (VNP40101M)), delays in the regulatory approval process, particularly for Onrigin (laromustine) Injection, including possible rejection by the F...
Cloretazine in Medical Technology

Vion Presents Data on Cloretazine (VNP40101M) at the 100th Annual Meeting of the American Association of Cancer Research (AACR)

NEW HAVEN, Conn., April 13, 2007 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. announced today that data on its lead anticancer agent Cloretazine(R) (VNP40101M) will be presented in posters at the 100th Annual Meeting of the American Association of Cancer Research in Los Angeles, California...

Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer

NEW HAVEN, Conn., June 04, 2007 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. announced that it presented updated clinical data in a poster session at the 43rd Annual Meeting of The American Society of Clinical Oncology (ASCO) on its lead anticancer agent Cloretazine(R) (VNP40101M) as a sin...

Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting

NEW HAVEN, Conn., June 11, 2007 /PRNewswire-FirstCall/ -- Vion Pharmaceuticals, Inc. announced that it presented clinical data in a poster session at the 12th Congress of the European Hematology Association (EHA) Meeting in Vienna, Austria on its lead anticancer agent Cloretazine(R) (VNP40101M) as...

Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients

...s clinical study to further evaluate the role that cloretazine can play in frontline AML therapy. This study will...rovide important information on the combination of cloretazine and induction therapy in patients with unfavorable...ission rate in these patients with the addition of cloretazine to a conventional induction regimen." The trial ...
Cloretazine in Biological Technology

Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM)

...xpected, including Vion's potential inability to obtain regulatory approval for its products, particularly Onrigin (laromustine) Injection (formerly cloretazine (VNP40101M)), delays in the regulatory approval process, particularly for Onrigin (laromustine) Injection, including possible rejection by the F...

Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting

...'s potential inability to file a New Drug Application or obtain regulatory approval for its products, particularly Onrigin(TM) (laromustine) (formerly cloretazine (R) (VNP40101M)), delays in the regulatory approval process or delays or unfavorable results of drug trials, the possibility that favorable results...
Other Tags
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is a comprehensive high-tech ... marketing of a series of induction heating equipment. Today, ... of induction brazing equipments . , According to ... refers to the joining of two or more ... manager says that there are fundamental differences in the ...
(Date:12/25/2014)... December 26, 2014 The report ... to 2023” focuses on the current treatment landscape, ... the colorectal cancer market. Stivarga is a drug ... or rectal cancer. Boehringer Ingelheim is developing nintedanib ... treatment of refractory CRC in the US, Europe, ...
(Date:12/25/2014)... 26, 2014 Recently, Dylan Queen, a ... excitedly released its collection of discounted prom dresses, most ... a senior spokesman of the company, the promotion is ... promotion is to expand the UK market. , The ... different colors, lengths, and styles: A-line strapless, empire strapless ...
(Date:12/25/2014)... When head lice hits a home or school, ... get rid of it while keeping it from taking over ... have the solution right in their neighborhood: Lice Troopers ... provides full spectrum head lice screening and treatment services to ... Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South Miami. ...
(Date:12/25/2014)... -- Among early stage breast cancer patients who undergo ... percent will eventually develop leukemia as a result of ... comes from a review of more than 20,000 breast ... suggests that the risk for developing treatment-related leukemia, though ... "The frequency of bone marrow cancers such as ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
(Date:12/17/2014)... Dec. 16, 2014 Research and Markets ... of the "Global Chemical Sensor Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 One major ... demand for medical sensors in biomedical applications. Chemical ... quick and correct diagnosis during surgical procedures. The ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has ... in the APAC Region 2015-2019"  report to their ... in this market is advances in technology. With ... upgrade biometric solutions to the latest standard that ...
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
Other Contents